Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Operating Expenses readings, the most recent being $185.0 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 48.58% to $185.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $660.8 million, a 32.97% increase, with the full-year FY2025 number at $600.3 million, up 28.04% from a year prior.
  • Operating Expenses hit $185.0 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $182.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $185.0 million in Q1 2026 to a low of $46.3 million in Q2 2022.
  • Median Operating Expenses over the past 5 years was $96.4 million (2024), compared with a mean of $103.5 million.
  • Biggest five-year swings in Operating Expenses: fell 3.98% in 2022 and later soared 70.24% in 2024.
  • Kiniksa Pharmaceuticals International's Operating Expenses stood at $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then skyrocketed by 70.24% to $141.8 million in 2024, then increased by 28.57% to $182.4 million in 2025, then rose by 1.45% to $185.0 million in 2026.
  • The last three reported values for Operating Expenses were $185.0 million (Q1 2026), $182.4 million (Q4 2025), and $156.8 million (Q3 2025) per Business Quant data.